The Pharmagellan Guide to Biotech Forecasting and Valuation

David MD PhD, Frank S./ Robey PhD, Seth/ Matthews MD, Andrew

ISBN 10: 099840750X / ISBN 13: 9780998407500

Editore: Pharmagellan, 2017

Riguardo questo articolo

1st edition. 138 pages. 9.00x6.00x0.35 inches. In Stock.

Codice articolo x-099840750X

Dati bibliografici

• Titolo: The Pharmagellan Guide to Biotech Forecasting and Valuation
• Editore: Pharmagellan
• Data di pubblicazione: 2017
• Lingua: Inglese
• ISBN 10: 099840750X
• ISBN 13: 9780998407500
• Rilegatura: Paperback
• Disegnatore: Clifton, Denise
• Condizione: Brand New
• Peso: 0,26 chilogrammi

Descrizione articolo

Riassunto

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.

THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.

• Vetted benchmarks for key drivers of income, expenses, and valuation.
• Proprietary analyses by Pharmagellan's experienced consulting team.
• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.

Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.

Informazioni sull?autore

Frank S. David, MD, PhD, is the founder and managing director of the biotech consultancy Pharmagellan (www.pharmagellan.com), an academic researcher and author on life sciences R&D, commercialization, and strategy, and a blogger about biomedical innovation at Forbes.com. He also maintains an active presence on Twitter (@Frank_S_David). Seth Robey, PhD, and Andrew Matthews, MD, are former and current associate consultants, respectively, at Pharmagellan.